
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Cancer Research, Vol 2, Issue 8 1307-1313, Copyright © 1996 by American Association for Cancer Research
ARTICLES |
A Frankel and GB Mills
Oncology Research Toronto Hospital, Toronto, Ontario, Canada M5G 2C4
Growth factors have been demonstrated to regulate the proliferation and viability of a number of cell lineages. Because most drugs used in chemotherapy kill cells through programmed cell death, by the process of apoptosis, we determined whether growth factors, specifically epidermal growth factor (EGF) and lysophosphatidic acid (LPA), which we have demonstrated recently to be a potent growth factor for ovarian cancer cells, would alter the ability of cis-diamminedichloroplatinum (cis-DDP), the most effective chemotherapeutic agent for ovarian cancer, to kill the HEY ovarian cancer cell line. We demonstrate that both EGF and LPA decrease the ability of cis-DDP to kill HEY ovarian cancer cells as assessed by colony-forming cell activity and dye reduction. Morphological changes, DNA release, and electron microscopy suggested that LPA and EGF protect ovarian cancer cells from programmed cell death induced by cis-DDP. Because LPA is present in high levels in ascitic fluid from ovarian cancer patients, and the EGF receptor is expressed by tumor cells from a significant portion of patients where it correlates with prognosis, growth factor modulation of cis-DDP-induced apoptosis may play a role in the poor prognosis associated with ovarian cancer.
This article has been cited by other articles:
![]() |
J. Chen, A. R. Baydoun, R. Xu, L. Deng, X. Liu, W. Zhu, L. Shi, X. Cong, S. Hu, and X. Chen Lysophosphatidic Acid Protects Mesenchymal Stem Cells Against Hypoxia and Serum Deprivation-Induced Apoptosis Stem Cells, January 1, 2008; 26(1): 135 - 145. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Murph, J. Hurst-Kennedy, V. Newton, D. N. Brindley, and H. Radhakrishna Lysophosphatidic Acid Decreases the Nuclear Localization and Cellular Abundance of the p53 Tumor Suppressor in A549 Lung Carcinoma Cells Mol. Cancer Res., November 1, 2007; 5(11): 1201 - 1211. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Klemm, S. Zimmermann, C. Peschel, T. W. Mak, and J. Ruland Bcl10 and Malt1 control lysophosphatidic acid-induced NF-{kappa}B activation and cytokine production PNAS, January 2, 2007; 104(1): 134 - 138. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Pilquil, J. Dewald, A. Cherney, I. Gorshkova, G. Tigyi, D. English, V. Natarajan, and D. N. Brindley Lipid Phosphate Phosphatase-1 Regulates Lysophosphatidate-induced Fibroblast Migration by Controlling Phospholipase D2-dependent Phosphatidate Generation J. Biol. Chem., December 15, 2006; 281(50): 38418 - 38429. [Abstract] [Full Text] [PDF] |
||||
![]() |
F.-q. Wang, Y. Smicun, N. Calluzzo, and D. A. Fishman Inhibition of Matrilysin Expression by Antisense or RNA Interference Decreases Lysophosphatidic Acid-Induced Epithelial Ovarian Cancer Invasion Mol. Cancer Res., November 1, 2006; 4(11): 831 - 841. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Macleod, P. Mullen, J. Sewell, G. Rabiasz, S. Lawrie, E. Miller, J. F. Smyth, and S. P. Langdon Altered ErbB Receptor Signaling and Gene Expression in Cisplatin-Resistant Ovarian Cancer Cancer Res., August 1, 2005; 65(15): 6789 - 6800. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Hu, N. Haney, D. Kropp, A. F. Kabore, J. B. Johnston, and S. B. Gibson Lysophosphatidic Acid (LPA) Protects Primary Chronic Lymphocytic Leukemia Cells from Apoptosis through LPA Receptor Activation of the Anti-apoptotic Protein AKT/PKB J. Biol. Chem., March 11, 2005; 280(10): 9498 - 9508. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Chou, L.-H. Wei, M.-L. Kuo, Y.-J. Huang, K.-P. Lai, C.-A. Chen, and C.-Y. Hsieh Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-{kappa}B pathway by lysophosphatidic acid, an ovarian cancer-activating factor Carcinogenesis, January 1, 2005; 26(1): 45 - 52. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Fang, S. Yu, R. C. Bast, S. Liu, H.-J. Xu, S.-X. Hu, R. LaPushin, F. X. Claret, B. B. Aggarwal, Y. Lu, et al. Mechanisms for Lysophosphatidic Acid-induced Cytokine Production in Ovarian Cancer Cells J. Biol. Chem., March 5, 2004; 279(10): 9653 - 9661. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lu, Y.-j. Xiao, L. M. Baudhuin, G. Hong, and Y. Xu Role of ether-linked lysophosphatidic acids in ovarian cancer cells J. Lipid Res., March 1, 2002; 43(3): 463 - 476. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Tigyi Selective Ligands for Lysophosphatidic Acid Receptor Subtypes: Gaining Control over the Endothelial Differentiation Gene Family Mol. Pharmacol., December 1, 2001; 60(6): 1161 - 1164. [Full Text] [PDF] |
||||
![]() |
J. J. A. Contos, I. Ishii, and J. Chun Lysophosphatidic Acid Receptors Mol. Pharmacol., April 13, 2001; 58(6): 1188 - 1196. [Abstract] [Full Text] |
||||
![]() |
A. Imai, T. Furui, T. Tamaya, and G. B. Mills A Gonadotropin-Releasing Hormone-Responsive Phosphatase Hydrolyses Lysophosphatidic Acid within the Plasma Membrane of Ovarian Cancer Cells J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3370 - 3375. [Abstract] [Full Text] |
||||
![]() |
A. M. Eder, T. Sasagawa, M. Mao, J. Aoki, and G. B. Mills Constitutive and Lysophosphatidic Acid (LPA)-induced LPA Production: Role of Phospholipase D and Phospholipase A2 Clin. Cancer Res., June 1, 2000; 6(6): 2482 - 2491. [Abstract] [Full Text] |
||||
![]() |
T. Furui, R. LaPushin, M. Mao, H. Khan, S. R. Watt, M.-A. V. Watt, Y. Lu, X. Fang, S. Tsutsui, Z. H. Siddik, et al. Overexpression of Edg-2/vzg-1 Induces Apoptosis and Anoikisin Ovarian Cancer Cells in a Lysophosphatidic Acid-independent Manner Clin. Cancer Res., December 1, 1999; 5(12): 4308 - 4318. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Xu, L. M. Love, I. Singh, Q.-X. Zhang, J. Dewald, D.-A. Wang, D. J. Fischer, G. Tigyi, L. G. Berthiaume, D. W. Waggoner, et al. Lipid Phosphate Phosphatase-1 and Ca2+ Control Lysophosphatidate Signaling through EDG-2 Receptors J. Biol. Chem., September 1, 2000; 275(36): 27520 - 27530. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |